Neoadjuvant chemotherapy with cisplatinum and 5-fluorouracil in advanced head and neck cancer.
Forty-one patients affected by solid tumors of the head and neck were treated with neoadjuvant therapy before radiotherapy or surgery. All patients received therapy with cisplatinum 100 mg/m2 day 1 and 5-fluorouracil 1000 mg/day for days 1-5 by continuous infusion with a portable chronoinfusor. After three cycles, we observed an objective response in 34/41 patients (82.9%), with 9 (21.9%) complete remissions and 25 (61%) partial remissions. The main side effects were few and controllable. In our experience, neoadjuvant chemotherapy was able to induce a significant remission in 4/5 of patients, with better prospects for subsequent surgery and/or radiotherapy.
Teatini
G
G
Department of Otorhinolaryngology, University of Sassari, Italy.
Meloni
F
F
Bisail
M
M
Milia
V
V
Sanna
G
G
Sarobba
M G
MG
Massidda
B
B
Scotto
T
T
Farris
A
A
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D012074:Remission Induction
D002945:Cisplatin; D005472:Fluorouracil